Fluticasone Propionate And Salmeterol Hfa Aerosol, Metered
Product Images NDC 66993-088

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol Hfa (NDC 66993-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fluticasone Chemical Structure (Fp Sal Hfa Spl Graphic 01)

Fluticasone Chemical Structure (Fp Sal Hfa Spl Graphic 01)
Chemical structure of fluticasone propionate, one of the active ingredients in Fluticasone Propionate and Salmeterol HFA aerosol inhalation.*
FDA Label Image

Salmeterol Chemical Structure (Fp Sal Hfa Spl Graphic 02)

Salmeterol Chemical Structure (Fp Sal Hfa Spl Graphic 02)
Chemical structure of the active ingredients fluticasone propionate and salmeterol xinafoate, shown as a structural formula diagram.*
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 03)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 03)
A line graph depicting the percentage change in FEV1 over 12 weeks and at endpoint for four groups: Fluticasone propionate and salmeterol HFA inhalation aerosol 45 mcg/21 mcg, Fluticasone propionate inhalation aerosol 44 mcg, Salmeterol inhalation aerosol 21 mcg, and placebo. The graph shows time on the x-axis (weeks) and percentage change in FEV1 on the y-axis, with each group represented by different markers.*
FDA Label Image

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Fp Sal Hfa Spl Image 04)

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Fp Sal Hfa Spl Image 04)
A line graph showing the percentage change in AM peak expiratory flow (PEF) over 12 weeks for three inhalation aerosols: Fluticasone propionate and salmeterol HFA 230 mcg/21 mcg (two inhalations twice daily), ADVAIR DISKUS 500 mcg/50 mcg (one inhalation twice daily), and Fluticasone propionate inhalation aerosol 220 mcg (two inhalations twice daily). The x-axis is labeled by week (0 to 12), and the y-axis shows percentage change in AM PEF, with point counts at selected weeks.*
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Image 05)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Image 05)
This line graph shows the percentage change in FEV1 over a 12-hour period for four groups: Fluticasone propionate and salmeterol HFA inhalation aerosol 45 mcg/21 mcg (two inhalations twice daily), fluticasone propionate inhalation aerosol 44 mcg (two inhalations twice daily), salmeterol inhalation aerosol 21 mcg (two inhalations twice daily), and placebo. The x-axis represents hours from baseline (day 1), and the y-axis represents the percent change in FEV1.*
FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Image 06)

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Image 06)
A line graph showing the percentage change in FEV1 relative to Day 1 baseline over 12 hours, comparing four groups: Fluticasone propionate and salmeterol HFA inhalation aerosol 45 mcg/21 mcg (triangles), Fluticasone propionate inhalation aerosol 44 mcg/2 inhalations (squares), Salmeterol inhalation aerosol 21 mcg/2 inhalations (circles), and Placebo (diamonds). The x-axis represents hours after dosing; the y-axis shows percentage change in FEV1.*
FDA Label Image

Figure A (Fp Sal Hfa Spl Image 07)

Figure A (Fp Sal Hfa Spl Image 07)
Illustration showing components of a Fluticasone Propionate and Salmeterol HFA metered aerosol inhaler, including the metal canister, purple plastic actuator, purple mouthpiece, counter, and a light purple cap detached from the mouthpiece.*
FDA Label Image

Figure B (Fp Sal Hfa Spl Image 08)

Figure B (Fp Sal Hfa Spl Image 08)
An instructional illustration showing hands removing the cap from the mouthpiece of a metered-dose inhaler. This diagram is related to the use of Fluticasone Propionate and Salmeterol HFA aerosol inhaler.*
FDA Label Image

Figure C (Fp Sal Hfa Spl Image 09)

Figure C (Fp Sal Hfa Spl Image 09)
An instructional illustration showing how to use a metered dose inhaler spray. The image depicts a person holding the inhaler with one hand, pressing down the canister to release the spray, with the head positioned to inhale the medication.*
FDA Label Image

Figure D (Fp Sal Hfa Spl Image 10)

Figure D (Fp Sal Hfa Spl Image 10)
Illustration showing a hand holding an inhaler device labeled with the number 120 on its side, indicating the dose counter. The inhaler is designed for respiratory inhalation use.*
FDA Label Image

Figure E (Fp Sal Hfa Spl Image 11)

Figure E (Fp Sal Hfa Spl Image 11)
An instructional illustration showing a hand holding a metered dose inhaler in the mouthpiece-down position. The device features a purple mouthpiece and a light purple cap is shown separately, indicating proper handling or assembly for inhalation use.*
FDA Label Image

Figure F (Fp Sal Hfa Spl Image 12)

Figure F (Fp Sal Hfa Spl Image 12)
Illustration showing a person's side profile instructing to breathe out as much air as possible. The image includes an arrow indicating airflow exiting the mouth, providing visual guidance on correct exhalation technique, likely related to use of a respiratory inhalation aerosol device.*
FDA Label Image

Figure G (Fp Sal Hfa Spl Image 13)

Figure G (Fp Sal Hfa Spl Image 13)
An instructional illustration showing proper use of a metered-dose inhaler. It depicts a person holding the inhaler near their mouth, with an arrow indicating where to breathe in while pressing the inhaler down.*
FDA Label Image

Figure H (Fp Sal Hfa Spl Image 14)

Figure H (Fp Sal Hfa Spl Image 14)
An instructional illustration showing a person rinsing their mouth by spitting water into a sink, with a glass of water and a faucet visible in the background. This likely demonstrates a step related to oral hygiene or medication use.*
FDA Label Image

Figure I (Fp Sal Hfa Spl Image 15)

Figure I (Fp Sal Hfa Spl Image 15)
An instructional diagram showing correct and blocked use of an aerosol inhaler. The top image labeled 'Not blocked' depicts the inhaler releasing a visible spray mist, while the bottom image labeled 'Blocked' shows no spray emitted, indicating improper use or obstruction of the inhaler's nozzle.*
FDA Label Image

Figure J (Fp Sal Hfa Spl Image 16)

Figure J (Fp Sal Hfa Spl Image 16)
An instructional illustration showing a hand holding a tool or stick to presumably activate or clean the nozzle of an aerosol inhaler device. The inhaler has an open cap revealing the mouthpiece with arrows indicating a rotating or twisting motion.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 45 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 17)

Fluticasone Propionate And Salmeterol Hfa 45 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 17)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol, 45 mcg/21 mcg strength. The metered aerosol inhaler by Prasco Laboratories provides 120 metered actuations with a net weight of 12 g. The label includes dosage form, active ingredients, use instructions specifying oral inhalation with the actuator only, and prescription-only status.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 115 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 18)

Fluticasone Propionate And Salmeterol Hfa 115 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 18)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol, 115 mcg/21 mcg strength by Prasco Laboratories. The label specifies it is for oral inhalation using the Fluticasone Propionate and Salmeterol HFA actuator only. It includes contents details, dosage form as aerosol metered inhalation, 120 metered actuations, and net weight of 12 g. The label features a small purple inhaler image on the lower right side and the NDC 66993-087-96.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 230 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 19)

Fluticasone Propionate And Salmeterol Hfa 230 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Image 19)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol, 230 mcg/21 mcg strength, from Prasco Laboratories. The label specifies a metered dose aerosol for oral inhalation, containing 120 metered actuations with a net weight of 12 g. The label highlights the contents and dosage form including the actuator type and inhalation route.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.